F Ceccherini-Silberstein

Summary

Affiliation: University of Rome Tor Vergata
Country: Italy

Publications

  1. doi Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure
    Valentina Svicher
    Department of Experimental Medicine, University of Tor Vergata Rome, Italy
    J Infect Dis 197:1408-18. 2008
  2. pmc Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage
    Salvatore Dimonte
    University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Retrovirology 8:33. 2011
  3. pmc Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs
    Claudia Alteri
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata Rome, Italy
    BMC Infect Dis 9:111. 2009
  4. pmc Identification of a novel Rev-interacting cellular protein
    Susanne Kramer-Hammerle
    Institute of Molecular Virology, GSF National Research Center for Environment and Health, Ingolstadter Landstrasse 1, D 85764 Neuherberg, Germany
    BMC Cell Biol 6:20. 2005
  5. pmc Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Antimicrob Agents Chemother 54:3938-48. 2010
  6. doi Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Antimicrob Chemother 65:2305-18. 2010
  7. pmc High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 79:10718-29. 2005
  8. pmc Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 81:11507-19. 2007
  9. ncbi Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Infect Dis 196:1180-90. 2007
  10. ncbi Characterization and structural analysis of HIV-1 integrase conservation
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    AIDS Rev 11:17-29. 2009

Detail Information

Publications42

  1. doi Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure
    Valentina Svicher
    Department of Experimental Medicine, University of Tor Vergata Rome, Italy
    J Infect Dis 197:1408-18. 2008
    ..We investigated the correlation of enfuvirtide (ENF)-associated gp41 mutational clusters with viroimmunological parameters, as well as the potential underlying mechanisms...
  2. pmc Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage
    Salvatore Dimonte
    University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Retrovirology 8:33. 2011
    ..The binomial correlation phi coefficient was used to assess covariation among gp120V3 and gp41 mutations; subsequently the average linkage hierarchical agglomerative clustering was performed...
  3. pmc Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs
    Claudia Alteri
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata Rome, Italy
    BMC Infect Dis 9:111. 2009
    ..This study is aimed to assess the prevalence and the patterns of the mutations recently associated with transmitted drug resistance in the reverse transcriptase (RT) and in protease (PR) of HIV-1...
  4. pmc Identification of a novel Rev-interacting cellular protein
    Susanne Kramer-Hammerle
    Institute of Molecular Virology, GSF National Research Center for Environment and Health, Ingolstadter Landstrasse 1, D 85764 Neuherberg, Germany
    BMC Cell Biol 6:20. 2005
    ..Identification of Rev-modulating cellular factors may eventually contribute to the design of novel antiviral therapies...
  5. pmc Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Antimicrob Agents Chemother 54:3938-48. 2010
    ....
  6. doi Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Antimicrob Chemother 65:2305-18. 2010
    ..To define whether the prevalence of mutations associated with integrase inhibitor (INI) resistance is different in untreated versus antiretroviral-treated HIV-1-infected individuals (all INI naive)...
  7. pmc High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 79:10718-29. 2005
    ..This new knowledge could be of help in the structure-based design of novel resistance-evading drugs...
  8. pmc Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 81:11507-19. 2007
    ..Mutations beyond those currently known to confer resistance should be considered for a better prediction of clinical response to reverse transcriptase inhibitors and for the development of more efficient new-generation NNRTIs...
  9. ncbi Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Infect Dis 196:1180-90. 2007
    ..A negative association between the polymorphism F214L and type 1 thymidine analogue (TA) mutations (TAMs) has been observed. However, the virological response to TAs according to the detection of F214L has not been evaluated...
  10. ncbi Characterization and structural analysis of HIV-1 integrase conservation
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    AIDS Rev 11:17-29. 2009
    ....
  11. doi The use of human immunodeficiency virus resistance tests in clinical practice
    F Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    Clin Microbiol Infect 16:1511-7. 2010
    ....
  12. doi Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure
    M Zaccarelli
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149, Rome, Italy
    Infection 37:203-9. 2009
    ..To assess the role of viral suppression on clinical progression following a genotypic resistance test (GRT), we have examined a database on patients failing to respond to combined antiretroviral therapy (cART)...
  13. ncbi Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir
    Maria Paola Trotta
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
    J Med Virol 78:535-41. 2006
    ..However, exposure to abacavir and/or efavirenz, presence of Q151M and/or L100I, and prior AIDS may favor the selection of this mutation. Conversely, long 3TC exposure, and the presence of M184V or NAMs seem to be protective...
  14. ncbi The V118I mutation as a marker of advanced HIV infection and disease progression
    Mauro Zaccarelli
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Antivir Ther 12:163-8. 2007
    ..We focused on the V1181 mutation in order to evaluate factors associated with its detection and its relationship with HIV progression...
  15. doi The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients
    M M Santoro
    University of Tor Vergata, Rome, Italy
    Clin Microbiol Infect 18:E289-98. 2012
    ....
  16. ncbi Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    J Infect Dis 189:1688-95. 2004
    ..We evaluated the effect of RT mutations associated with hypersusceptibility to NNRTIs on the response to efavirenz-based therapy...
  17. doi Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008
    M C F Prosperi
    Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    HIV Med 12:174-82. 2011
    ....
  18. doi Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients
    M M Santoro
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
    Infection 37:233-43. 2009
    ..To date, however, genotypic resistance scores (GRSs) have been developed only for boosted-ATV. We have determined GRS associated with virologic response (VR) for both ATV300/r and ATV400 in highly pre-treated HIV-1 infected patients...
  19. pmc Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria
    Maria Mercedes Santoro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    AIDS Res Hum Retroviruses 24:1133-8. 2008
    ..Furthermore, surveillance of PR and RT sequences is also convenient to monitor the introduction of nonsubtype B HIV-1 strains in Bulgaria...
  20. ncbi Temporal change in the use of genotypic resistance testing over the years 1999--2003
    M Santoro
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    New Microbiol 27:141-4. 2004
    ..0001). Overall, data suggest that the genotype test is increasingly considered, and requested also for patients at earlier stages of drug history and/or at less severe disease stage...
  21. doi Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study
    M C F Prosperi
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Clin Infect Dis 50:1316-21. 2010
    ..9-3.1 cases per 1000 person-years of follow-up), respectively. Lower current CD4 cell count was an independent predictor of developing malignancies, with the association being stronger for ADM than for NADM...
  22. doi The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Hepatol 50:461-70. 2009
    ..To investigate the different clusters of mutations associated with lamivudine resistance in HBV genotypes D and A...
  23. doi Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Acquir Immune Defic Syndr 55:336-44. 2010
    ..To investigate genotypic resistance profiles to emtricitabine + tenofovir (FTC + TDF) in-vivo and in-vitro, and compare them with lamivudine + tenofovir (3TC + TDF)...
  24. doi Dynamics of NRTI resistance mutations during therapy interruption
    Maria Trignetti
    Experimental Medicine Department, University of Rome Tor Vergata, 00133, Rome, Italy
    AIDS Res Hum Retroviruses 25:57-64. 2009
    ..Overall, it seems that the loss of NRTI drug resistance mutations during TI is not an ordered process, and in the majority of patients occurs without specific interaction among mutations...
  25. pmc Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Antimicrob Agents Chemother 53:2816-23. 2009
    ..This highlights the multiple roles of ENF (and perhaps other entry inhibitors) in modulating the correct interplay between the different HIV-1 genes and proteins during the HIV-1 life cycle...
  26. ncbi Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome
    J Antimicrob Chemother 55:872-8. 2005
    ....
  27. ncbi Virologic correlates of adherence to antiretroviral medications and therapeutic failure
    Carlo Federico Perno
    INMI L Spallanzani, Rome, Italy
    J Acquir Immune Defic Syndr 31:S118-22. 2002
    ....
  28. ncbi Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group
    Valentina Svicher
    University of Rome Tor Vergata, Department of Experimental Medicine, Roma, Italy
    New Microbiol 33:195-206. 2010
    ..The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trofile (ESTA) as reference-assay...
  29. doi Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir
    Chiara Tommasi
    National Institute for Infectious Diseases, INMI, L Spallanzani, Rome, Italy
    Scand J Infect Dis 42:237-9. 2010
    ..We describe the clinical outcome of a heavily antiretroviral-experienced patient who experienced early failure to raltegravir...
  30. ncbi Molecular diversity of HIV in Albania
    Massimo Ciccozzi
    Epidemiology Unit, Department of Infectious Diseases, Istituto Superiore di Sanita, Rome, Italy
    J Infect Dis 192:475-9. 2005
    ..In conclusion, non-B subtypes are predominant in Albania, and the prevalence of resistance to antiretroviral drugs is still low...
  31. doi Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues
    Mm Santoro
    University of Rome Tor Vergata, Rome, Italy
    HIV Med 14:571-7. 2013
    ....
  32. ncbi Historical resistance profile helps to predict salvage failure
    Mauro Zaccarelli
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Antivir Ther 14:285-91. 2009
    ....
  33. ncbi HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment
    Carlo Federico Perno
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Scand J Infect Dis Suppl 106:37-40. 2003
    ....
  34. ncbi Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Italy
    AIDS 18:F11-9. 2004
    ..To define the extent of amino acid protease (PR) conservation in vivo in the absence and presence of pharmacological pressure in a large patient cohort...
  35. ncbi The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs
    Joeri Auwerx
    Rega Institute for Medical Research, K U Leuven, Belgium
    FEBS Lett 579:2294-300. 2005
    ....
  36. ncbi Novel drug resistance mutations in HIV: recognition and clinical relevance
    Carlo Federico Perno
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Italy
    AIDS Rev 8:179-90. 2006
    ..Such novel mutations should be considered for improved prediction of clinical response to antiretroviral drugs and for assessing the efficacy of next-generation drugs...
  37. pmc Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 80:7186-98. 2006
    ....
  38. ncbi Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy
    Maria Mercedes Santoro
    Department of Experimental Medicine, Tor Vergata University of Rome, Italy
    New Microbiol 29:89-100. 2006
    ....
  39. ncbi Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation
    Andrea Antinori
    National Institute for Infectious Diseases L Spallanzani IRCCS, Roma, Italy
    Antivir Ther 12:1175-83. 2007
    ..The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined...
  40. ncbi The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors
    Jan Balzarini
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    Mol Pharmacol 68:49-60. 2005
    ....
  41. pmc Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Antimicrob Agents Chemother 49:2015-25. 2005
    ....
  42. ncbi The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A
    Joeri Auwerx
    Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    Mol Pharmacol 68:652-9. 2005
    ....